Introduction
B-Myb is a member of a small family of genes that includes two other known members, A-Myb and c-Myb (Nomura et al., 1988) . Whereas A-Myb and c-Myb are expressed in restricted tissues, expression of B-Myb is ubiquitous in proliferating somatic cells (Nomura et al., 1988; Sitzmann et al., 1996) . The Myb proteins are localised to the cell nucleus and bind a PyAACG/TG consensus DNA sequence (Biedenkapp et al., 1988) , designated the Myb binding site (MBS). DNA-binding is mediated through a comparatively large aminoterminal domain (Howe et al., 1990; Oehler et al., 1990) which demonstrates a high degree of conservation within this protein family. All three members of the Myb protein family have been reported to activate transcription from responsive promoters (Nishina et al., 1989; Weston and Bishop, 1989; Mizuguchi et al., 1990; Foos et al., 1994; Golay et al., 1994; Ma and Calabretta, 1994; Takahashi et al., 1995) , however, there are distinct dierences in their transcription regulatory properties, particularly between c-Myb and B-Myb. Transactivation by c-Myb requires only the DNA binding domain and a weakly acidic region (amino acids 275 ± 325) which is conserved in A-Myb but not in B-Myb (Sakura et al., 1989; Weston and Bishop, 1989) . The C-terminal half of the c-Myb protein downstream of the activation domain is implicated in negative regulation of transactivation activity (Kalkbrenner et al., 1990; Hu et al., 1991; Dubendor et al., 1992) . Several distinct c-Myb motifs appear to be involved in negative regulation, including a putative leucine zipper and the recently described EVES motif, which participates in intramolecular recognition of the DNA-binding domain (Dash et al., 1996) . These motifs are either incompletely conserved or absent, respectively, in AMyb and B-Myb.
In contrast to c-Myb and A-Myb, transactivation by B-Myb appears to be notably tissue-speci®c (Tashiro et al., 1995) . In mouse NIH3T3 and chicken HD11 ®broblasts, B-Myb was unable to transactivate Mybresponsive promoters, and indeed when co-expressed competitively inhibited the activity of c-Myb on these promoters (Foos et al., 1992; Watson et al., 1993) . Moreover, B-Myb has been demonstrated to repress type I collagen gene expression in smooth muscle cells (Marhamati and Sonensheim, 1996) . In light of such ®ndings and the fact that B-Myb lacks the activation domain conserved between c-Myb and A-Myb, it has been suggested that B-Myb may be an inhibitory member of the Myb family (Foos et al., 1992) . Other studies have shown, however, that B-Myb is a transactivator in monkey CV1 and human HeLa cell lines (Mizuguchi et al., 1990; Nakagoshi et al., 1992; Tashiro et al., 1995) . Again in contrast to c-Myb and A-Myb, two regions of B-Myb downstream of the DNA-binding domain were shown to be required for this activity (Nakagoshi et al., 1993) : an acidic region (amino acids 207 ± 373) which is topologically approximately equivalent to the c-Myb activation domin (but otherwise entirely unrelated) and a C-terminal conserved sequence (amino acids 468 ± 545) which demonstrates signi®cant homology with both c-Myb and AMyb as well as with Myb proteins described in distantly related species such as Drosophila melanogaster. It is notable that this study found no evidence for a negative regulatory domain in the B-Myb C-terminus (Nakagoshi et al., 1993) . Even in CV1 cells, B-Myb was found in comparison to c-Myb to be a weak activator of a reporter comprising an SV40 early promoter into which multiple upstream MBS had been inserted (Mizuguchi et al., 1990) . Curiously, the MBS appeared to be dispensable for B-Myb activation of this reporter, suggesting that B-Myb may be binding an unrelated site in the SV40 promoter (Nakagoshi et al., 1993) .
A number of lines of evidence indicate that B-Myb plays a general role in cell proliferation. B-Myb transcription is strictly cell cycle regulated by the E2F transcription factor resulting in maximal B-Myb protein levels during Sphase (Robinson et al., 1996) . Consistent with this, antisense DNA and RNA experiments show a requirement for B-Myb in cell proliferation (Arsura et al., 1992; Sala and Calabretta, 1992) . That this requirement is manifested during G 1 /S transition or Sphase itself is indicated by the ®nding that B-Myb overexpression results in alterations in the cell cycle pro®le, such that a greater proportion of cells are in Sphase (Sala et al., 1996) . In addition, B-Myb overexpression was found both to overcome G 1 blocks mediated by either p53 or p107 (Lin et al., 1994; Sala et al., 1996) and to prevent growth arrest associated with terminal dierentiation of monocytic cells (Bies et al., 1996) .
Previously we have noted that the B-Myb protein undergoes a phosphorylation event in S-phase resulting in decreased electrophoretic mobility (Robinson et al., Figure 1 Sequence-speci®c B-Myb transactivation activity. (a) Diagrams of the basic pT81luc and the pT81luc 3xA luciferase reporters. The three mim-1 A Myb binding sites (MBS) are shown upstream of the TK promoter in T81luc 3xA. (b) U-2 OS cells were transfected with either the pT81luc or the pT81luc 3xA reporters together with empty vector plasmids (CON), pSVB-myb (BMyb) or a combination of pCMVcycA (B-Myb+CycA). Luciferase assays were performed on cell extracts made 2 days following transfection and the average values of duplicate transfections are presented. (c) Further transfections were performed in U-2 OS cells using pT81luc 3xA as the reporter. These cells were co-transfected with empty vector plasmids (CON), pCMVcdk2DN (Cdk2DN), pCMVCycA (CycA), pSVB-myb (B-Myb) and combinations of these plasmids as indicated. Luciferase values, the average of at least four experiments, are presented relative to that of the control (assigned a value of unity). Standard deviations are indicated 1996). The timing of this event was unaected by ectopic expression of B-Myb through G 1 , implicating an S-phase-speci®c kinase in this modi®cation. The most likely candidate for this activity was therefore the cyclin A/cdk2 complex, and consistent with this conclusion we found that B-Myb was a substrate for this enzyme complex in baculovirus-infected insect cells (Robinson et al., 1996) . The coincidence between the timing of maximal B-Myb mRNA expression and the phosphorylation in S-phase suggested that the modi®ed form of B-Myb may be hyperactivated. We report here studies which suggest that cyclic A/Cdk2 can indeed potentiate both the transcriptional transactivation function of B-Myb and its ability to promote cells into the S-phase of the cycle.
Results

Cyclin A enhances MBS-speci®c transactivation function of B-Myb
Previous studies have shown that B-Myb transactivation activity is markedly cell type-speci®c (Tashiro et al., 1995) . To investigate the possible in¯uence of cyclin A-mediated modi®cation on B-Myb function, therefore, it was ®rst necessary to identify a suitable cell background for these experiments. Initially a number of cell lines were assessed for their abilities to support activation of a Myb-responsive promoter/reporter, pT81luc 3xA (Ness et al., 1989) , in transient cotransfection assays with the expression plasmid, pSVBmyb (data not shown). This study revealed low but consistent transactivation activity in the U-2 OS human osteosarcoma cell line, comparable to the activity found in CV1 cells, however, little or no activity was apparent in Saos-2 human osteosarcoma cells or in the C33A cervical carcinoma cell line. Further assays were then carried out to determine whether transactivation of pT81luc 3xA by B-Myb in U-2 OS cells was dependent upon the MBS sites in the promoter. Moreover, we also investigated whether cotransfection of a cyclin A expression plasmid, pCMVcycA, would aect B-Myb transactivation properties. The ®vefold transactivation of T81luc 3xA by B-Myb observed in this experiment (Figure 1 ) was largely dependent upon the MBS, as B-Myb had a negligible eect on the control pT81luc reporter which lacks these sites. Signi®cantly, co-transfection of pCMVcycA with pSVB-myb enhanced the level of transactivation of pT81luc 3xA approximately 28-fold, whereas this combination had only a small eect on the control pT81luc reporter (Figure 1b) .
To demonstrate that the ability of cyclin A to potentiate B-Myb function was mediated by cdk activity, further reporter assays were carried out in the presence of a dominant-negative Cdk2 protein, speci®ed by pCMVcdk2DN. Co-transfection of pCMVcdk2DN had no signi®cant eect upon transactivation of pT81luc 3xA by B-Myb alone, however, it abolished the ability of cyclin A to enhance this activity ( Figure 1c ). It is also notable that cyclin A had little eect on reporter activity in the absence of cotransfected B-Myb ( Figure 1c ). It is clear, therefore, that cyclin A/Cdk2 kinase activity speci®cally enhanced the sequence-speci®c transactivation function of BMyb.
Modi®cation of B-Myb correlates with potentiation of transactivation activity
Previous studies using a baculovirus expression system showed that B-Myb is a direct target for cyclin A/Cdk2 kinase activity (Robinson et al., 1996) , and the most
Figure 2 B-Myb modi®cation correlates with enhancement of transactivation activity. U-2 OS cells were transfected with the pT81luc 3xA reporter together with the empty pCMV vector, pCMVcycA, pCMVcycA and pCMVcdk2 or pCMVcdk2Dn and either the empty pSV vector (CON) or pSVB-myb. (a) Luciferase values, the average of duplicate transfections, are shown relative to the control pCMV (assigned a value of unity). (b) Extracts from parallel transfections were analysed by Western blotting using the BM-2 antibody raised against B-Myb likely explanation for the enhancement of B-Myb transactivation activity by this enzyme complex is that phosphorylation potentiates B-Myb function. To corroborate these ®ndings, it was clearly important to demonstrate that the enhancement of B-Myb transactivation function was correlated with modi®cation. Extracts of U-2 OS cells transfected with pSVB-myb in combination with plasmids encoding cyclin A, Cdk2 and Cdk2DN were therefore analysed by Western blotting to detect the transfected B-Myb protein; further extracts were assayed for luciferase activity speci®ed by co-transfected pT81luc 3xA reporter. As anticipated, co-transfection of pCMVcycA with pSVBmyb resulted (Figure 2a ) in an enhancement of reporter luciferase activity compared to cells transfected with pSVB-myb alone (33-fold and ®vefold, respectively, compared to the reporter only control). It is notable that co-transfection of pSVB-myb with both pCMV cycA and pCMVcdk2 led to a further enhancement of reporter activity (78-fold compared to the reporter only control). This latter eect was largely dependent on the transfected B-Myb, as cyclin A/Cdk2 alone activated the reporter only sixfold (Figure 2a) .
Analysis of the transfected B-Myb protein ( Figure  2b ) showed that enhancement of transactivation function correlated closely with its modi®cation to an electrophoretically less mobile form, designated BMyb-P, similar to that seen previously in serumstimulated mouse ®broblasts upon entry into S-phase (Robinson et al., 1996) . Thus, in cells co-transfected with pSVB-myb and the empty pCMV vector, B-Myb was predominantly in an ostensibly unmodi®ed form (Figure 2b ), while co-transfection with pCMVcycA resulted in a readily detectable shift of a signi®cant proportion to the modi®ed B-Myb-P form. Significantly, in cells co-transfected with both pCMVcycA and pCMVcdk2 virtually all the B-Myb protein was in the modi®ed form (Figure 2b ). This incremental increase in B-Myb modi®cation therefore correlates well with the progressive enhancement of B-Myb transactivation function elicited by cyclin A expression and cyclin A/Cdk2 co-expression in these cells ( Figure  2a) . It is notable that no dierences in electrophoretic mobility were discernible between B-Myb in U-2 OS cells co-transfected with pCMVcdk2DN or the pCMV control, indicating that the input B-Myb protein did not undergo an obvious modi®cation in the absence of transfected cdk components.
C-terminal truncation of B-Myb also enhances transactivation activity
The mouse B-Myb protein contains 22 sites with the minimum speci®city (Ser/Thr-Pro) for cdk phosphorylation, the majority of which are in the C-terminal half of the protein (Figure 3a) . To begin to determine whether removal of some of these sites would aect BMyb transactivation properties, activation of the pT81luc 3xA reporter was tested with C-terminally truncated B-Myb proteins. Unexpectedly, it was found that truncation of the C-terminal coding sequence at a SacI restriction enzyme site (generating plasmid pSVBmyb.Sac: amino acids 1 ± 561) dramatically increased B-Myb transactivation activity compared to the wildtype protein (Figure 3b) . Further deletion using a ScaI site (pSVB-myb.Sca: amino acids 1 ± 508) resulted in complete loss of transactivation activity while further deletion at an AatII site (pSVB-myb.Aat: amino acids 1 ± 350) resulted in recovery of residual activity at approximately half the level of the wild-type protein (Figure 3b ). Further transfection experiments in which the input of pSVB-myb and pSVB-myb.Sac was compared over a range of 1 ± 20 mg showed that transactivation of pT81luc 3xA was approximately 20-fold greater with the deleted construct at all inputs tested (Figure 3c) . Control experiments using the basic pT81luc reporter showed that pSVB-myc.Sac activity in these assays was dependent on the MBS (data not shown). In part these results are consistent with published results in which it was shown that both the acidic and conserved regions (CR) are required for BMyb transactivation activity (Nakagoshi et al., 1993) , though it should be noted that in this previous study activation of the reporter was not MBS-dependent. Morever, our results show that the acidic domain by itself can contribute a low level of transactivation activity. In addition, our results show that the B-Myb C-terminus (amino acids 562 ± 704) acts to limit transactivation activity and may therefore constitute a negative regulatory domain.
This study has demonstrated that B-Myb activity can be potentiated in two ways: cyclin-dependent phosphorylation and removal of the C-terminus. An attractive model to rationalise these observations is that phosphorylation induces a conformational change in B-Myb that renders a C-terminal regulatory region non-functional. If this were so, it was predicted that pSVB-myb.Sac activity would not be further enhanced by cdk-mediated modi®cation. In co-transfection assays to test this prediction (Figure 4) , cyclin A and Cdk2 alone elicited Figure 4 Full-length B-Myb is more responsive to cdk-mediated modi®cation than the pSVB-myc.Sac product. (a) U-2 OS cells were transfected with the pT81luc 3xA reporter together with the empty pSV vector, pSVB-myb or pSVB-myb.Sac. These cells additionally received pCMV, pCMVcycA, pCMVcdk2 or a combination of pCMVcycA and pCMVcdk2 as indicated. Luciferase values, the average of duplicate transfections, are expressed relative to that obtained with the pSV plus pCMV control. (b) Results are also shown for multiple experiments (at least four transfections) performed as in (a). These results are expressed for transfected cells receiving the eector plasmids pSV, pSVB-myb and pSVB-myb.Sac (transfected also with pCMVcycA, pCMVcdk2 or a combination of these two plasmids) relative to the values obtained in each case for the pCMV control. Thus, the fold activation is a measure of the enhancement of eector plasmid activity by the co-transfected cyclin A or Cdk2 only an additional 1.5-fold increase in pSVB-myb.Sac transactivation activity, while a combination of both cyclin A/Cdk2 increased transactivation by approximately threefold. A similar level of reporter activation was found in controls that received the empty pSV vector, suggesting either that this eect re¯ects endogenous B-Myb activity or that cyclin A/Cdk2 stimulates a general transcriptional component. In contrast, cyclin A/Cdk2 potentiated pSVB-myb transactivation by 13-fold (Figure 4b ). As the B-Myb expression plasmid inputs used (5 mg) were clearly suboptimal (Figure 3c ), these data indicate that full length B-Myb is more responsive to cdk-mediated modi®cation than the C-terminally truncated pSVB-myb.Sac product. It is notable, however, that although a combination of cyclin A/Cdk2 results in complete conversion to the B-Myb-P form (Figure 2b ), the level of transactivation obtained with pSVB-myb was appreciably lower than obtained with pSVB-myb.Sac under similar conditions ( Figure  4a ), suggesting that phosphorylation can only partially overcome the transactivation block imposed by the BMyb C-terminus. These data therefore suggest that cyclin A expression additionally aects B-Myb activity through another mechanism, possibly its ability to interact with co-activators.
B-Myb truncation enhances transactivation activity in NIH3T3 cells
Previous studies have indicated that B-Myb has little or no ability to transactivate Myb-responsive genes in NIH3T3 cells Tashiro et al., 1995) . In light of the ®ndings that cdk-mediated phosphorylation and C-terminal protein truncation enhanced this activity in U-2 OS cells, we asked whether these treatments would uncover latent B-Myb transactivation function in NIH3T3 cells. It was found that the pT81luc 3xA reporter had a low basal activity in these cells, at a level similar to that seen previously in U-2 OS cells. In contrast to previous studies using a dierent Myb-responsive reporter Tashiro et al., 1995) , this basal activity could actually be activated modestly (2.5-fold) in NIH3T3 cells by pSVB-myb, however, it could not be signi®cantly enhanced further by cyclin A alone or even in combination with Cdk2 ( Figure 5 ). In some contrast, the truncated pSVB-myb.Sac construct activated the reporter 17-fold in these cells ( Figure 5 ). This latter activity was slightly enhanced by cyclin A (to 29-fold), however, a combination of cyclin A/Cdk2 was unable to enhance the level of transactivation, suggesting that the kinase complex had no signi®cant eect on B-Myb activity in NIH3T3 cells. These ®ndings suggest that the relative inactivity of B-Myb in NIH3T3 cells does not re¯ect an inherent de®ciency of its activation domains in this cell line. Rather, these data point to the possibility that B-Myb is indierent to coactivation signals, in part mediated by protein phosphorylation, in NIH3T3 cells but is able to respond to these signals in U-2 OS cells.
Cyclin A synergises with B-Myb to promote cells into Sphase
Previous studies have shown that B-Myb overexpression alters the distribution of human glioblastoma T98G cells within the cell cycle by increasing the proportion in S-phase (Sala et al., 1996) . As it is now apparent that cyclin A can potentiate B-Myb activity, we reasoned that cyclin A may synergise with B-Myb to promote U-2 OS cells into S-phase. To test this supposition, U-2 OS cells were transiently transfected with combinations of pSVB-myb and pCMVcycA together with a plasmid encoding the CD20 cell surface protein. Following sequential staining with ā uorescein isothiocyanate-tagged CD20 antibody and propidium iodide, transfected and untransfected cells were discriminated by¯ow cytometry and the cell cycle pro®les of both populations were analysed. An example of these analyses is shown in Figure 6 , where it is apparent that transfection of pSVB-myb and pCMVcycA individually had little or no eect on the proportion of cell in S-phase. In contrast, cotransfection of both pSVB-myb and pCMVcycA induced a shift in the cell cycle pro®le of the CD20-positive transfected cell population, such that a signi®cantly greater proportion were in S-phase ( Figure 6 ). Synergism between B-Myb and cyclin A was observed in a number of additional independent experiments (Table 1) . These ®ndings are consistent with the notion that B-Myb-P is an activated protein isoform, however, it can not be discounted that this synergism re¯ects the combined activity of B-Myb and cyclin A on independent pathways.
Discussion
We have demonstrated here that B-Myb transactivation activity can be markedly potentiated by two Figure 5 The truncated pSVB-myb.Sac product is a transactivator in NIH3T3 cells. NIH3T3 cells were transfected with pSV, pSVB-myb or pSVB-myc.Sac together with the pCMV control, pCMVcycA or a combination of pCMVcycA and pCMVcdk2. Luciferase activities, the average of duplicate transfections, are shown relative to that of the pSV/pCMV control mechanisms: cyclin A/Cdk2-mediated phosphorylation and protein truncation. Surprisingly, previous studies of B-Myb function have failed to ®nd evidence that transactivation was mediated through MBS, even in cells where B-Myb could be shown unequivocably to activate Myb-responsive promoter/reporters (Nakagoshi et al., 1993) . While it is apparent that activation of pT81luc 3xA depends upon B-Myb binding to the MBS, there is yet no indication that phosphorylation alters the B-Myb DNA binding properties. Previous studies have shown that DNA binding activity could not be detected with the full length B-Myb protein, even when this was translated in vitro ; DNA-binding was revealed progressively, however, upon incremental C-terminal deletion, suggesting that the B-Myb C-terminus masked the DNA-binding domain. Recent studies (SL and RW, unpublished observations) have indicated similarly that baculovirus-expressed full-length B-Myb has no detectable in vitro DNA-binding activity, moreover, cdkmediated phosphorylation of this protein failed to induce this activity. Although not unequivocal, these results at least suggest that the enhanced activity associated with B-Myb-P does not result from an increased capacity to bind DNA. On the other hand, it is conceivable that the C-terminal truncation incurred by the pSVB-myb.Sac product does increase DNAbinding potential compared to the wild-type protein, and that this phenomenon underlies the increased transactivation activity of the truncated product. This may explain why previous studies (Nakagoshi et al., 1993) , where B-Myb transactivation was largely independent of MBS binding, did not reveal an enhancement of transactivation activity by truncation of the B-Myb C-terminus.
In view of the arguments above, it must be assumed that cdk-mediated phosphorylation has direct eects upon the ability of B-Myb to activate transcription when bound to the promoter. Consistent with previous ®ndings (Nakagoshi et al., 1993) , we have observed that B-Myb can activate certain promoters which lack recognisable MBS in U-2 OS cells, such as the minimal SV40 early promoter and the murine BMyb promoter itself, and that this activity is also enhanced by co-transfection with pCMVcycA (SL and RW, unpublished observations). Possibly, activation of promoters lacking MBS re¯ects an indirect association with cis-binding sites mediated through physical interaction of B-Myb with other transcription factors. It may be suggested, both in this situation and where B-Myb interacts directly with the MBS, that cdk-mediated phosphorylation enhances B-Myb/ accessory protein interactions, resulting in potentiation of transactivation. It is of interest to note that cellular proteins binding to the B-Myb CR, which is essential for transactivation, have been detected by an in vitro interaction assay (Tashiro et al., 1995) . The spectrum of proteins interacting with the CR were dierent in cells regarded as permissive for B-Myb transactivation (e.g. CV-1 cells) than in cells in which B-Myb transactivation function could not be detected (e.g. NIH3T3 cells). The B-Myb CR sequence used in this assay (amino acids 434 ± 558) contains many potential cdk phosphorylation sites (Figure 4 ) and it may be speculated that modi®cation of sites within this region facilitates interaction between B-Myb and speci®c coactivators or transcriptional adapators in cells such as CV-1, whereas in NIH3T3 cells the accessory proteins responsive to B-Myb phosphorylation are absent or less abundant. It is important to recognise, however, that the truncated pSVB-myb.Sac protein did activate the pT81luc 3xA reporter in NIH3T3 cells, albeit the fold activation was notably less than in U-2 OS cells. Indeed, even the full-length B-Myb activated this reporter to a low level in NIH3T3 cells. It appears most likely, therefore, that cellular permissivity for B- Figure 6 B-Myb co-operates with cyclin A to promote U-2 OS cells into S-phase. U-2 OS cells were transfected with empty vector controls (vector), pCMVcycA (cyclin A), pSVB-myb (BMyb) or a combination of pCMVcycA and pSVB-myb (BMyb+cyclin A). In each case, transfections also contained a plasmid encoding the CD20 cell surface protein. Cells were collected 2 days after transfection and stained successively with ā uoroscein-labelled CD20 antibody and propidium iodide (PI). Cells expressing the transfected DNA (CD20+ve) were discriminated from those not expressing the marker (CD20 7ve) by FACS analysis and cell cycle pro®les (PI staining) were plotted on histograms for both populations of cells Myb transactivation function is not`all or nothing'. Thus, the activation function of B-Myb most likely diers over a range in dierent cell types, possibly depending both upon the promoter context and the abundance of accessory proteins required for transcriptional activation. If it is considered that B-Myb does have transactivation function in all cell types, albeit varying over a range, it is easier to conceptualise a general role for its function in cell cycle progression. Clearly, it will be important to examine further the ability of B-Myb to promote cells into S-phase in a number of cell types.
Current and previous ®ndings indicate that B-Myb expression is regulated at two levels during the cell cycle, induction of transcription mediated by E2F/pocket protein interactions and activation of the protein function by phosphorylation, together resulting in the production of abundant hyperactivated B-Myb speci®cally in Sphase. Control of B-Myb expression at these two levels by distinct cdk-mediated events strongly suggests that the B-Myb protein is a signi®cant component of cell cycle regulatory mechanisms. Indeed, inhibition of BMyb expression by antisense approaches has indicated a strict requirement for B-Myb function in cell proliferation (Arsura et al., 1992; Sala and Calabretta, 1992) . Moreover, overexpression of B-Myb has been found both to promote cells into the S-phase of the cycle as well as to overcome inhibitory blocks mediated by p53 and p107 (Sala and Calabretta, 1992; Lin et al., 1994; Sala et al., 1996) , again suggesting an important role for B-Myb in cell cycle regulation. It remains a matter of speculation what this role is, though it seems most plausible that it involves transcriptional activation of genes whose products are involved directly in DNA synthesis.
The data presented here and previously (Robinson et al., 1996) are both consistent with the notion that BMyb is an in vivo target for the cyclin A/Cdk2 complex. Other data (SL and RW, unpublished observations) suggest that cyclin E/Cdk2 and cyclin D1/Cdk4 complexes can potentiate B-Myb transactivation function, though neither of these cdks was as active as cyclin A/Cdk2 in this respect. Therefore, both the timing of B-Myb modi®cation during S-phase and its relative ecacy suggest that cyclin A/Cdk2 is the enzyme responsible in vivo. Previously it has been shown that cyclin A expression is mandatory for the onset and maintenance of DNA synthesis in mammalian cells (Girard et al., 1991; Pagano et al., 1992) . As cyclin A was found to synergise with B-Myb to promote cells into S-phase (Figure 6 ), it will be of interest to explore further the possibility that the requirement for cyclin A for DNA synthesis re¯ects, at least in part, enhancement of B-Myb by direct phosphorylation.
Materials and methods
Plasmids
The pT81luc 3xA reporter containing three MBS (representing the chicken mim-1 A site) upstream of a minimal herpes simplex virus thymidine kinase promoter and the basic pT81luc reporter lacking the MBS have been described previously (Nordeen, 1988; Ness et al., 1989) .
The mouse B-Myb expression vector pSVB-myb has been described . C-terminal truncations of the B-Myb coding sequence were made in pSVB-Myb by cutting with the AatII, ScaI or SacI restriction enzymes together with another enzyme which cuts at a 3' vector polylinker site; appropriate oligonucleotides containing a termination codon were then inserted. Plasmids encoding human cyclin A, Cdk2 and Cdk2DN under control of the cytomegalovirus immediate-early promoter (pCMVcycA, pCMVcdk2 and pCMVcdk2DN) have been described by their originators (Hinds et al., 1992; van den Heuvel and Harlow, 1993) .
Cell culture
The human osteosarcoma cell line U-2 OS was obtained from ATCC and maintained in Dulbecco's modi®ed Eagle's medium (DMEM) containing 10% fetal calf serum. NIH3T3 cells were maintained in DMEM containing 10% newborn calf serum. Cells plated at 50% con¯uency in 60 mm dishes were transfected by overnight exposure to calcium phosphate co-precipitates as described previously . Precipitates contained 5 mg of the pT81luc 3xA or pT81 luc reporters together with, where appropriate, 5 mg pSVB-myb (or the truncated derivatives) and 2 mg of pCMVcycA, pCMVcdk2 or pCMVcdk2DN. All precipitates contained 2 mg pSV2-bgal and where necessary a balancing amount of the empty pSV and pCMV vectors. For reporter gene assays, cell lysates were made 2 days after addition of the precipitate and assayed for luciferase and b-galactosidase activities as delineated previously . Extracts for B-Myb protein analyses were also made 2 days after transfection by freeze-thawing. These cells were ®rst washed three times with PBS, then resuspended in the equivalent of ®ve packed cell volumes of 100 mM HEPES, pH 7.4, 500 mM KCl, 5 mM MgCl 2 , 5 mM NaF, 0.5 mM EDTA and 35% glycerol. After thorough freezing at 7708C, the lysed cells were incubated on ice for 30 min then the cellular debris was removed by centrifugation at 100 000 g for 30 min.
Western blot analysis
B-Myb protein in freeze-thaw extracts was analysed by Western blotting using the BM-2 polyclonal antibody raised to the C-terminus (amino acids 516 ± 704) of mouse B-Myb (Robinson et al., 1996) . Bound antibody was detected by the ECL chemiluminescence reaction (Amersham) as described previously (Robinson et al., 1996) .
FACS analysis
Cell cycle analyses of pSVB-myb and pCMVcycA transfected cells were performed essentially as described previously (Sala et al., 1996) . U-2 OS cells seeded at 50% con¯uency on 10 cm dishes were transfected with 20 mg pSVB-myb (or the empty pSV vector), 10 mg pCMVcycA (or the empty pCMV vector) and 2 mg of pCMVCD20 (encoding the CD20 cell surface protein) by overnight exposure to calcium phosphate co-precipitates. Two days after transfection, cells were detached by washing with 3 mM EDTA in PBS, then stained with¯uoroscein isothiocyanate-labelled CD20 antibodies (Becton-Dickinson). After overnight ®xation at 48C with 70% ethanol, cells were stained in PBS containing 18 mg/ml propidium iodide and 8 mg/ml RNase A for 30 min at room temperature in the dark. Transfected CD20 positive cells were discriminated from untransfected cells by¯ow cytometry with a Becton-Dickinson FACSort using the FL1 channel and cell cycle pro®les were obtained for both populations using standard procedures (Sala et al., 1996) .
